MediPharm Labs and Cronos Group Enter Private Label Contract Manufacturing Agreement

MediPharm Labs与Cronos签订自有大麻品牌合同制造协议

2019-09-20 09:15:40 CFN Media Group

本文共1454个字,阅读需4分钟

MediPharm to produce high-quality cannabis concentrate filled vapes for Cronos Group Deal reinforces MediPharm Labs’ leadership in large scale manufacturing and distribution.  MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”), a leader in specialized, research-driven cannabis extraction and cannabinoid isolation, is pleased to announce that it has signed a multi-year contract manufacturing agreement (“CMA”) for the filling and packaging of vaporizer devices, subject to approval by Health Canada, for Cronos Group Inc.’s (NASDAQ:CRON) (TSX:CRON) (“Cronos Group”) adult-use brand, COVE™. MediPharm Labs Inc. (“MediPharm”), a wholly-owned subsidiary of the Company, and a wholly-owned subsidiary of Cronos Group, entered into a CMA where MediPharm, utilizing its proprietary expertise and equipment, will provide filling of high-quality formulated concentrate, labelling and packaging services to exacting specifications at scale for Cronos Group. The initial term of the agreement is two years with an option for renewal. “On the eve of legalization of concentrates products in Canada, we are delighted to add Cronos Group, to our expanding turnkey white-label platform,” said Pat McCutcheon, CEO of MediPharm Labs. “By leveraging our specialized expertise, technology and industrial scale vape filling capabilities, we will assist Cronos Group in delivering high quality, purity assured and Health Canada approved, derivative products further advancing their industry leading reputation and enhancing the supply chain in this important new category.” This is the second collaboration between the companies. In May 2019, MediPharm Labs signed a multi-year private label bulk resin supply agreement and a cannabis concentrate program agreement with Cronos Group. “Working with MediPharm Labs gives us the quality and optionality that we are looking for as we introduce our proprietary vape pen formulations,” said Mike Gorenstein, CEO of Cronos Group. “We are committed to continuing to the lead the industry responsibly as derivative products are introduced to the expanding Canadian marketplace.” About Cronos Group Inc. Cronos Group is an innovative global cannabinoid company with international production and distribution across five continents. Cronos Group is committed to building disruptive intellectual property by advancing cannabis research, technology and product development. With a passion to responsibly elevate the consumer experience, Cronos Group is building an iconic brand portfolio. Cronos Group’s portfolio includes PEACE NATURALS™, a global health and wellness platform, and two adult-use brands, COVE™ and Spinach™. To learn more about Cronos Group and its brands, please visit: www.thecronosgroup.com; www.peacenaturals.com; www.covecannabis.ca; www.spinachcannabis.com About MediPharm Labs Founded in 2015, MediPharm Labs specializes in the production of purified, pharmaceutical-like cannabis oil and concentrates and advanced derivative products utilizing a Good Manufacturing Practices designed facility and ISO standard built clean rooms. MediPharm Labs has invested in an expert, research driven team, state-of-the-art technology, downstream purification methodologies and purpose-built facilities with five primary extraction lines having 300,000 kg of annual processing capacity to deliver pure, safe and precisely dosed cannabis products for its customers. Through its wholesale, white label and tolling platforms, they formulate, process, package and distribute cannabis extracts and advanced cannabinoid-based products to domestic and international markets. As a global leader, the Company also completed its first commercial export to Australia in June 2019 and is nearing completion of its Australian extraction facility expected in 2019 with 75,000 kg of annual processing capacity.
为克罗诺斯集团生产高质量大麻浓缩物填充vapes的医药公司 该交易加强了Medipharm Labs在大规模生产和分销领域的领导地位。Medipharm Labs Corp.(TSX:Labs)(OTCQX:Medif)(FSE:MLZ)(简称“Medipharm Labs”或“公司”),一家专业的、研究驱动的大麻提取和大麻素分离领域的领导者,很高兴宣布其已签署了一份多年合同制造协议(“CMA”),以供Cronos Group Inc.的成人用品品牌Cove™填充和包装汽化器设备,该协议须经加拿大卫生部批准。 Medipharm Labs Inc.(“Medipharm”)是公司的全资子公司,也是Cronos Group的全资子公司,与CMA签订协议,Medipharm将利用其专有专业知识和设备,提供高质量配方浓缩液的灌装、标签和包装。为cronos组提供按比例严格规范的服务。协议的初始期限为两年,可选择续签。 Medipharm Labs首席执行官帕特•麦库琴(Pat McCutcheon)表示:“在加拿大浓缩液产品合法化前夕,我们很高兴将克罗诺斯集团(Cronos Group)加入我们不断扩大的交钥匙白色标签平台。”“通过利用我们的专业知识、技术和工业规模的VAPE填充能力,我们将协助克洛诺斯集团提供高质量、纯度保证和加拿大卫生部批准的衍生产品,进一步提高其行业领先的声誉和提高供应这是一个重要的新类别。” 这是两家公司之间的第二次合作。2019年5月,Medipharm Labs与Cronos Group签署了一份多年期私有标签散装树脂供应协议和大麻浓缩物项目协议。 克罗诺斯集团首席执行官迈克•戈伦斯坦(Mike Gorenstein)说:“与Medipharm实验室合作,使我们在引进我们的专利VAPE笔配方时,能够获得所需的质量和可选性。”“随着衍生产品被引入不断扩大的加拿大市场,我们致力于以负责任的态度继续引领行业。” 关于克罗诺斯集团公司。 克洛诺斯集团是一家创新的全球大麻素公司,其国际生产和分销遍及五大洲。克罗诺斯集团致力于通过推进大麻研究、技术和产品开发来建立破坏性知识产权。凭借负责任地提升消费者体验的热情,克洛诺斯集团正在打造一个标志性的品牌组合。Cronos Group的产品组合包括Peace Naturals™,一个全球健康平台,以及两个成人用品品牌Cove™和Spinach™。欲了解更多关于克罗诺斯集团及其品牌的信息,请访问:www.thecronosgroup.com;www.peacenaturals.com;www.covephania.ca;www.spinachphania.com 关于医学实验室 Medipharm Labs成立于2015年,专业生产纯净的、制药类的大麻油、浓缩物和高级衍生产品,利用良好的生产实践设计的设施和ISO标准建造的洁净室。Medipharm实验室已投资于一个专家、研究驱动团队、最先进的技术、下游净化方法和专门建造的设施,其中五条初级提取线的年处理能力为300000公斤,可输送纯净水,为客户提供安全、精确的大麻产品。他们通过其批发、白色标签和收费平台,制定、加工、包装大麻提取物和以大麻素为基础的先进产品,并将其分销到国内和国际市场。作为一家全球领先企业,该公司还于2019年6月完成了对澳大利亚的首次商业出口,并接近于2019年完成其澳大利亚开采设施,预计年处理能力为75000公斤。

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文